前收市價 | 0.4000 |
開市 | 無 |
買盤 | 0.0000 |
賣出價 | 1.9500 |
拍板 | 22.50 |
到期日 | 2024-05-17 |
今日波幅 | 0.4000 - 0.4000 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 1 |
QIAGEN's (QGEN) solid potential in the NGS platform buoys optimism for investors.
QIAGEN's (QGEN) Clinical Insight Interpret is the first NGS interpretation platform approved by IVDR for use in cancer and hereditary applications.
QIAGEN (QGEN) receives FDA clearance for the QIAstat-Dx respiratory syndromic testing panel for fast and accurate results.